业务咨询




| CYP | Inhibitor | Substrate | Reaction | Metabolite |
|---|---|---|---|---|
| 1A2 | α-Naphthoflavon | Phenacetin | Phenacetin O-deethylation | Acetaminophen |
| 2B6 | Clopidogrel | Bupropion | Bupropion-hydroxylation | Hydroxybupropion |
| 2C8 | Nicardipine | Paclitaxel | Paclitaxel 6α-hydroxylation | 6α-hydroxy Paclitaxel |
| 2C9 | Sulfaphenazole | Diclofenac | Diclofenac 4'-hydroxylation | 4'-hydroxy diclofenac |
| 2C19 | Omerazole | S-Mephenytoin | s-Mephenytoin 4'-hydroxylation | 4-Hydroxy Mephenytoin |
| 2D6 | Quinidine | Dextromethorphan | Dextromethorphan O-demethylation | Dextrorphan |
| 3A4-T | Ketoconazole | Testosterone | Testosterone 6β-hydroxylation | 6β-hydroxy Testosterone |
| 3A4-M | Ketoconazole | Midazolam | Midazolam 1-hydroxylation | Mida1'-hydroxy Midazolam |

| Study Type | Workflow (DAys) | Compound Requirement (Mg)* |
|---|---|---|
| 大鼠PK | 5 | 15 |
| 小鼠PK:连续采样 | 5 | 5 |
| 小鼠PK:平行采样 | 5 | 10 |
| 大鼠BBB实验 | 3 | 10 |
| 小鼠BBB实验 | 3 | 5 |
| 复合式给药PK | 5 | 15 |



| 单个化合物给药 | 复合物给药 | ||
| 优势 | 劣势 | 优势 | 劣势 |
|---|---|---|---|
| 无药物相互作用 | 使用较多动物 | 使用较少动物 | 潜在的药物相互作用 |
| 剂量耐受较高 | 分析样品较多 | 分析样品较少 | 单个化合物剂量耐受较低 |
| 单一化合物报告,报告较多 | 分析方法较复杂 | ||

